The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
Open accessAbstract
Satisfactory management of Parkinson’s disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D 1 - and D 2 -like receptor agonist, is the only drug proven to have an efficacy equal to that of levodopa, albeit with a shorter time to onset and effect duration. Clinical trials have shown that intermittent apomorphine injections provide rapid and effective relief from unpredictable “off” periods. Continuous apomorphine infusion reduced around 50% of the daily “off” time in several studies. Dopaminergic side effects such as nausea, somnolence and hypotonia, as well as administration site reactions, are often mild or treatable, but somnolence and skin reactions in particular can sometimes be reasons for premature discontinuation. We provide an overview of the pharmacological mechanism of action of the drug in light of its effects on Parkinson’s disease symptoms. We then summarize the evidence regarding the efficacy and tolerability of apomorphine, both in its established formulations (subcutaneous intermittent injection and continuous infusion) and in the new preparations currently under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Moore, T. J., Glenmullen, J., & Mattison, D. R. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5262 · Cited by 324
Cited by
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Church, F. C. (2021) · Biomolecules · doi:10.3390/biom11040612 · Cited by 290
Bian, X., Wang, Q., Wang, Y., & Lou, S. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1305208 · Cited by 15
Metadata
- Authors
- Carbone, F., Djamshidian, A., Seppi, K., & Poewe, W.
- Venue
- CNS Drugs
- Published
- 2019-08-31
- Volume
- 33
- Issue
- 9
- Pages
- 905-918
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2971102518
- Cited by
- 190
- References
- 2
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. https://app.cochat.ai/papers/10.1007/s40263-019-00661-z
- The paper
- Carbone, F., Djamshidian, A., Seppi, K., & Poewe, W. (2019). Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. https://doi.org/10.1007/s40263-019-00661-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.